/

BridgeBio Pharma, Inc.

BBIO US

BBIO USBridgeBio Pharma, Inc.

United States Composite

25.77

USD

-1.06

(-3.95%)

-3.95EPS Dil.

-6.52P/E

4.51BMarket Cap

Next Earnings

May 2

Held by Insiders

5.37%

Held by Institutions

91.93%

Short % of Float

7.76%

YTD Yield

86.97%

3Y Yield

-50.00%

Capital Structure

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

ST Debt

LT Borrowings

1,719

1,721

1,727

LT Finance Leases

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

161

174

175

Market Capitalization

2,776

4,592

7,068

Working Capital

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

Total Current Assets

433

588

478

Cash, Cash Equivalents & STI

384

543

435

Accounts Receivable, Net

- -

Inventories

- -

Total Current Liabilities

110

106

144

Payables & Accruals

ST Debt

Deferred Revenue

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

- -

-88.46%

Net Income, GAAP

-NaN%

-43.15%

-33.68%

Free Cash Flow

-NaN%

-32.10%

-24.18%

Total Cash Common Dividend

- -

Total Equity

-NaN%

-200.91%

-7.87%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

2022

2023

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

-1.18

-0.66

-1.06

-1.01

-3.90

2022

-1.35

-0.07

-0.93

-0.92

-3.26

2023

-0.92

-0.98

-1.08

-0.96

-3.95

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Company Description

CEO: Dr. Neil Kumar Ph.D.
Full Time Employees: 550
Sector: Healthcare
Industry: Biotechnology
Address: 3160 Porter Drive Palo Alto CA United States 94304
CIK: 0001743881
Website: bridgebio.com
Business: BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Company News

Tipranks
20 days ago
TipRanks’ ‘Perfect 10’ List: These 3 Top-Scoring Stocks Are Sending a Bullish Signal
Zacks
22 days ago
Bayer (BAYRY) Banks on Pipeline Progress Amid Challenges
Tipranks
23 days ago
Buy Rating Justified for BridgeBio Pharma Amidst Promising Long-Term Market Prospects for ATTR-CM Treatments
Yahoo
a month ago
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Tipranks
a month ago
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Jazz Pharmaceuticals (JAZZ)
Yahoo
a month ago
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
Yahoo
a month ago
Bayer (BAYRY) Acquires BridgeBio's Cardiovascular Drug
Zacks
a month ago
Bayer (BAYRY) Acquires BridgeBio's Cardiovascular Drug
Tipranks
a month ago
Analysts Are Bullish on These Healthcare Stocks: BridgeBio Pharma (BBIO), Elevance Health (ELV)
Tipranks
a month ago
Analysts’ Top Healthcare Picks: Avidity Biosciences (RNA), Irhythm Technologies (IRTC)

Company Description

CEO: Dr. Neil Kumar Ph.D.
Full Time Employees: 550
Sector: Healthcare
Industry: Biotechnology
Address: 3160 Porter Drive Palo Alto CA United States 94304
CIK: 0001743881
Website: bridgebio.com
Business: BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Company News

Tipranks
20 days ago
TipRanks’ ‘Perfect 10’ List: These 3 Top-Scoring Stocks Are Sending a Bullish Signal
Zacks
22 days ago
Bayer (BAYRY) Banks on Pipeline Progress Amid Challenges
Tipranks
23 days ago
Buy Rating Justified for BridgeBio Pharma Amidst Promising Long-Term Market Prospects for ATTR-CM Treatments
Yahoo
a month ago
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Tipranks
a month ago
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Jazz Pharmaceuticals (JAZZ)
Yahoo
a month ago
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
Yahoo
a month ago
Bayer (BAYRY) Acquires BridgeBio's Cardiovascular Drug
Zacks
a month ago
Bayer (BAYRY) Acquires BridgeBio's Cardiovascular Drug
Tipranks
a month ago
Analysts Are Bullish on These Healthcare Stocks: BridgeBio Pharma (BBIO), Elevance Health (ELV)
Tipranks
a month ago
Analysts’ Top Healthcare Picks: Avidity Biosciences (RNA), Irhythm Technologies (IRTC)